We then investigated whether any of the abovementioned genes were upregulated with the use of pyrotinib and whether this could be abrogated with the introduction of dalpiciclib, which may serve as a potential risk factor in the treatment of HER2+HR+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.